|4Jun 15, 4:29 PM ET

KISNER DANIEL L 4

4 · Zynerba Pharmaceuticals, Inc. · Filed Jun 15, 2023

Insider Transaction Report

Form 4
Period: 2023-06-13
Transactions
  • Award

    Common Stock

    2023-06-13+47,82475,893 total
  • Award

    Stock Option (right to buy)

    2023-06-13+71,73671,736 total
    Exercise: $0.35Exp: 2033-06-13Common Stock (71,736 underlying)
  • Sale

    Common Stock

    2023-06-14$0.35/sh115$4075,778 total
Footnotes (3)
  • [F1]The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders.
  • [F2]This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
  • [F3]The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders.

Documents

2 files
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

  • EX-24.1